NAUT Insider Trading
Insider Ownership Percentage: 40.50%
Insider Buying (Last 12 Months): $62,622.00
Insider Selling (Last 12 Months): $234,728.97
Nautilus Biotechnology Insider Trading History Chart
This chart shows the insider buying and selling history at Nautilus Biotechnology by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Nautilus Biotechnology Share Price & Price History
Current Price: $0.89
Price Change: ▲ Price Increase of +0.162 (22.41%)
As of 05/13/2025 11:32 AM ET
Nautilus Biotechnology Insider Trading History
Nautilus Biotechnology Institutional Trading History
Data available starting January 2016
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More on Nautilus Biotechnology
Volume
70,112 shs
Average Volume
112,679 shs
Market Capitalization
$111.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.41
Who are the company insiders with the largest holdings of Nautilus Biotechnology?
Who are the major institutional investors of Nautilus Biotechnology?
Which major investors are buying Nautilus Biotechnology stock?
During the last quarter, NAUT stock was bought by institutional investors including:
- Clarius Group LLC
- Nuveen LLC
- Fayez Sarofim & Co
- XTX Topco Ltd
- Deutsche Bank AG
- Sentinel Trust Co. LBA
In the previous year, these company insiders have bought Nautilus Biotechnology stock:
- Parag Mallick (Insider)
- Sujal M Patel (CEO)
Learn More investors buying Nautilus Biotechnology stock.